Repaglinide dose response? A clinician's viewpoint.
Schade
D S
DS
Department of Internal Medicine, Division of Endocrinology & Metabolism, University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, USA. dschade@salud.unm.edu
D001786:Blood Glucose / Q000378:metabolism; D002219:Carbamates / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D015444:Exercise; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D015431:Weight Loss
D001786:Blood Glucose; D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; C072379:repaglinide